More about High-Yield Cash Accounts with M1
Brokerage Accounts
Retirement Accounts
Other Accounts
Quotes are delayed by 15 minutes.
1D
1W
1M
3M
6M
YTD
1Y
2Y
5Y
ALL
Market cap
$19.38B
EPS
-3.69
P/E ratio
--
Price to sales
19
Dividend yield
--
Beta
1.679211
Previous close
$144.03
Today's open
$148.57
Day's range
$141.04 - $149
52 week range
$74.55 - $191.05
show more
CEO
Helmy Eltoukhy
Employees
2506
Headquarters
Palo Alto, CA
Exchange
Nasdaq Global Select
Shares outstanding
135285975
Issue type
Common Stock
Healthcare
Medical Diagnostics & Screening
Guardant Health Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
PALO ALTO, Calif.--(BUSINESS WIRE)--Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, today announced that on October 13, 2026, the Compensation Committee of Guardant's Board of Directors approved the granting of restricted stock units (“RSUs”) representing 86,192 shares of its common stock to 118 new non-executive employees with a grant date of November 9, 2026, under the Guardant Health, Inc. 2023 Employment Inducement Incentive Award Plan (the “Inducement Plan”). The.
Business Wire • Nov 13, 2026

Guardant Health Prices $500 Million Convertible Senior Notes Offering
PALO ALTO, Calif.--(BUSINESS WIRE)---- $GH--Guardant Health, Inc. (“Guardant Health”) (Nasdaq: GH), a leading precision oncology company, today announced the pricing of its offering of $500 million aggregate principal amount of 0% convertible senior notes due 2032 (the “notes”) in a private offering (the “offering”) to persons reasonably believed to be qualified institutional buyers pursuant to Rule 144A under the Securities Act of 1933, as amended (the “Securities Act”). The issuance and sale of the n.
Business Wire • Nov 12, 2026

Guardant Health Introduces New Epigenomic Applications Providing Deeper Insights for Treatment Selection with Guardant360® Liquid
PALO ALTO, Calif.--(BUSINESS WIRE)--Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, today announced new applications for Guardant360® Liquid designed to help oncologists understand how a patient's cancer may respond to treatment in the absence of traditional biomarkers. The expanded capabilities include five key advances: Two novel epigenomic predictors identify patients that may benefit from selective estrogen receptor degraders (SERDs) in advanced breast cancer and i.
Business Wire • Nov 11, 2026

Guardant Health Announces Proposed $500.0 Million Offering of Convertible Senior Notes Due 2032
PALO ALTO, Calif.--(BUSINESS WIRE)---- $GH--Guardant Health, Inc. (“Guardant Health”) (Nasdaq: GH), a leading precision oncology company, today announced its intention to offer $500.0 million aggregate principal amount of convertible senior notes due 2032 (the “notes”) in a private offering (the “offering”) to persons reasonably believed to be qualified institutional buyers pursuant to Rule 144A under the Securities Act of 1933, as amended (the “Securities Act”). Guardant Health also intends to grant t.
Business Wire • Nov 11, 2026

PRECISION Study Published in ESMO Open Highlights Utility of Guardant360® Liquid and Guardant Reveal® to Assess Recurrence Risk After Surgery for Colorectal Cancer Metastases
PALO ALTO, Calif.--(BUSINESS WIRE)--Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, today announced that ESMO Open has published results from PRECISION, a prospective multicenter observational study in Japan that enrolled 130 patients and evaluated complementary blood-based approaches for assessing recurrence risk in patients undergoing curative-intent surgery for colorectal cancer metastases. The study paired pretreatment comprehensive genomic profiling (CGP) using Gu.
Business Wire • Nov 10, 2026

Guardant Health to Participate in Upcoming Investor Conferences
PALO ALTO, Calif.--(BUSINESS WIRE)---- $GH--Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, today announced the company will be participating in the following investor conferences. Jefferies Global Healthcare Conference in London, UK Fireside chat on Wednesday, November 18 at 3:00 p.m. Greenwich Mean Time Piper Sandler 38th Annual Healthcare Conference in New York, NY Fireside chat on Tuesday, December 1 at 8:00 a.m. Eastern Time Interested parties may access live and archived.
Business Wire • Nov 9, 2026

What Guardant Health (GH) Said on Its Q3 Earnings Call
Guardant Health NASDAQ: GH raised its full-year 2026 revenue forecast after third-quarter sales increased 36%, driven by growth in its oncology testing business and demand for its Shield blood-based cancer screening test.
MarketBeat • Nov 6, 2026

Guardant Health, Inc. (GH) Q3 2026 Earnings Call Transcript
Guardant Health, Inc. (GH) Q3 2026 Earnings Call Transcript
Seeking Alpha • Nov 6, 2026

Guardant Health Reports Third Quarter 2026 Financial Results and Increases 2026 Revenue Guidance
PALO ALTO, Calif.--(BUSINESS WIRE)---- $GH--Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, today reported financial results for the quarter ended September 30, 2026. Third Quarter 2026 Financial Highlights For the three-month period ended September 30, 2026, as compared to the same period of 2025: Reported total revenue of $361.0 million, an increase of 36%, driven by: Oncology revenue of $231.3 million, an increase of 25%, and 117,000 oncology tests, an increase of 58% Bioph.
Business Wire • Nov 5, 2026

Guardant Health (GH) Q3 Earnings: How Key Metrics Compare to Wall Street Estimates
The headline numbers for Guardant Health (GH) give insight into how the company performed in the quarter ended September 2026, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.
Zacks Investment Research • Nov 6, 2026

¹ Disclosures

Open an M1 investment account to buy and sell Guardant Health Inc. commission-free¹. Build wealth for the long term using automated trading and transfers.